LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).
1 finding from 1 review
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes onlyOR 0.66 [0.27, 1.63]4 studies · 2860 participantsModerate